Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment

Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer

(2020) Shipeng He et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity

(2020) Chunhui Cheng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response

(2020) Wei-Cheng Wu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

(2020) Jayesh Desai et al.   JOURNAL OF CLINICAL ONCOLOGY

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors

(2020) Ashish Thakur et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Novel Dual Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin (mTOR) Target Inhibitor as a Promising Strategy for Cancer Therapy

(2019) Yong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

(2019) Xuewu Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Overview of HDAC Inhibitors and their Synthetic Routes

(2019) Xiaopeng Peng et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro

(2019) Shuangxi Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases

(2019) Kehui Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2

(2019) Yu Yu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors

(2019) Aixin Geng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors

(2019) Baolei Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy

(2019) Zigao Yuan et al.   BIOORGANIC CHEMISTRY

N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PDL-1 expression

(2019) Samir Mehndiratta et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug

(2019) Jingkao Chen et al.   INVESTIGATIONAL NEW DRUGS

The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair

(2019) Bin Deng et al.   DNA AND CELL BIOLOGY

Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide

(2019) Ying Wu et al.   ACS Medicinal Chemistry Letters

Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - a new hybrid design paradigm

(2018) Anthony F. Palermo et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors

(2018) Mitsuaki Yamashita et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors

(2018) Jiwei Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold

(2018) Jian Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)

(2018) Lianbin Yao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma

(2018) Yuqin Zhang et al.   BMC CANCER

1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC

(2018) Ritu Ojha et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors

(2018) Sandra Atlante et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors

(2018) Raffaella Cincinelli et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

BCL-2 as therapeutic target for hematological malignancies

(2018) Guilherme Fleury Perini et al.   Journal of Hematology & Oncology

Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma

(2018) Dizhong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

(2018) Yahui Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

(2018) Jie Zang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on isocombretastatin A-4

(2018) Diana Lamaa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer

(2018) Krikor Bijian et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer

(2018) Heba M. Hesham et al.   MEDICINAL RESEARCH REVIEWS

Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties

(2018) Rui Xie et al.   MedChemComm

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors

(2018) Kun Fang et al.   ACS Medicinal Chemistry Letters

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

(2018) Yu-yi Chu-Farseeva et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents

(2018) Raffaella Cincinelli et al.   PLoS One

Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy

(2018) Yingchao Duan et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

(2018) Ruolan Zhou et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

(2018) Bastian von Tresckow et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

(2018) Mei-Jung Lai et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor

(2018) Sanil Bhatia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents

(2018) Gaoliang Cheng et al.   BIOORGANIC CHEMISTRY

Vitamin D receptor as a target for breast cancer therapy

(2017) Alyson Murray et al.   ENDOCRINE-RELATED CANCER

Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment

(2017) Ying-Chao Duan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1

(2017) Zichen Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

(2017) Yuankai Shi et al.   Journal of Hematology & Oncology

Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors

(2017) Guoqiang Dong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

(2017) Lianbin Yao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives

(2017) Dong Lu et al.   ACS Medicinal Chemistry Letters

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery

(2017) Wei Chen et al.   ACS Medicinal Chemistry Letters

Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors

(2017) Lanlan Zang et al.   Oncotarget

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

(2017) Yin Li et al.   Clinical Epigenetics

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Inhibitors of histone deacetylase as antitumor agents: A critical review

(2016) Mohammed Manal et al.   BIOORGANIC CHEMISTRY

The emerging role of serum/glucocorticoid-regulated kinases in cancer

(2016) Pau Castel et al.   CELL CYCLE

Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors

(2016) Jie Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC

(2016) Fan-Wei Peng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

(2016) Yi Liao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

(2016) Eugene Guorong Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

(2016) Yves Pommier et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

(2016) Sherri Z. Millis et al.   JAMA Oncology

Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition

(2016) Jing Ma et al.   Scientific Reports

The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101

(2015) Thomas Mehrling et al.   Anti-Cancer Agents in Medicinal Chemistry

Perspectives in the development of hybrid bifunctional antitumour agents

(2015) Loana Musso et al.   BIOCHEMICAL PHARMACOLOGY

Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase

(2015) Fan-Wei Peng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer

(2015) Jian Geng et al.   CANCER LETTERS

Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway

(2015) Xiao Liu et al.   CANCER SCIENCE

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

(2015) T. J. Galloway et al.   CLINICAL CANCER RESEARCH

Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids

(2015) Quaovi H. Sodji et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo

(2015) Min-Wu Chao et al.   Journal of Hematology & Oncology

Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance

(2015) Peter Bai   MOLECULAR CELL

Epigenetic modifications of histone H3 during the transdifferentiation of Thy-1(+) Lin(−) bone marrow cells into hepatocytes

(2015) XINXIN LIAO et al.   Molecular Medicine Reports

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

Homocysteine Induces Collagen I Expression by Downregulating Histone Methyltransferase G9a

(2015) Wenjing Lei et al.   PLoS One

Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling

(2015) Shun Li et al.   TUMOR BIOLOGY

Effect of HDAC-6 on PD cell induced by lactacystin

(2015) Li-Fei Xing et al.   Asian Pacific Journal of Tropical Medicine

Functional Role of G9a Histone Methyltransferase in Cancer

(2015) Francesco Casciello et al.   Frontiers in Immunology

TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma

(2014) Shuai Shuai et al.   CANCER LETTERS

VEGF Signal System: The Application of Antiangiogenesis

(2014) Xuewu Liang et al.   CURRENT MEDICINAL CHEMISTRY

The methyltransferase G9a regulates HoxA9-dependent transcription in AML

(2014) B. Lehnertz et al.   GENES & DEVELOPMENT

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

(2014) Lei Zhang et al.   MEDICINAL RESEARCH REVIEWS

The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis

(2014) Kuo-Tai Hua et al.   Molecular Cancer

DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis

(2014) Zhaojin Yu et al.   MOLECULAR CARCINOGENESIS

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease

(2014) Shalome Bassett et al.   Nutrients

Dual-acting histone deacetylase-topoisomerase I inhibitors

(2013) William Guerrant et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation

(2013) Stacey M. Frumm et al.   CHEMISTRY & BIOLOGY

Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment

(2013) Konstantinos A Papavassiliou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3

(2013) FANLIANG MENG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

(2013) Craig S. Takeuchi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment

(2013) Jhih-Bin Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

(2013) Nicola J. Curtin et al.   MOLECULAR ASPECTS OF MEDICINE

Metabolic targets for cancer therapy

(2013) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo

(2013) Eva Juengel et al.   PLoS One

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

Tamoxifen Resistance in Breast Cancer

(2012) Min-Sun Chang   Biomolecules & Therapeutics

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries

(2012) Takayoshi Suzuki et al.   JOURNAL OF MEDICINAL CHEMISTRY

Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors

(2012) Francesca Musumeci et al.   JOURNAL OF MEDICINAL CHEMISTRY

Conjugate of Pt(IV)–Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy

(2012) Jun Yang et al.   MOLECULAR PHARMACEUTICS

Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications

(2011) Ana Custodio et al.   CANCER TREATMENT REVIEWS

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Entinostat for treatment of solid tumors and hematologic malignancies

(2011) Jeffrey Knipstein et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo

(2011) Valentina Zuco et al.   PLoS One

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

(2010) Cheng-Jung Lai et al.   CANCER RESEARCH

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

(2010) Paul A Marks   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers

(2010) Shinya Hayami et al.   INTERNATIONAL JOURNAL OF CANCER

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

(2010) Xiong Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity

(2010) Siavosh Mahboobi et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer

(2009) Viraj B. Gandhi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases†

(2009) Siavosh Mahboobi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

(2009) S. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease

(2008) Antonio Macchiarulo et al.   AMINO ACIDS

SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway

(2008) A Hrzenjak et al.   JOURNAL OF PATHOLOGY

DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines

(2008) J Devon Roll et al.   Molecular Cancer